SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

GLENMARK PHARMACEUTICALS

BSE: 532296 29 Jun 2025
Healthcare
₹ 1691
Glenmark Pharmaceuticals ltd specializes in Pharmaceuticals within the Healthcare sector.

GLENMARK PHARMACEUTICALS - Share Price & Details

Market Cap
₹48,290
High /Low
1,831 / 1,230
Stock P/E
36.6
Book Value
₹314.0
Dividend Yield
0.15
ROCE
19.4
ROE
₹15.8
Face Value
1.0
PEG Ratio
3.11
EVEBITDA
₹19.9
Debt
2,473
CMP / FCF
-54.4
Debt to equity
₹0.28
NP Ann
1,047
High price all time
1,831
Piotroski score
₹5.0
Graham Number
512.0
No. Eq. Shares
28.2
Net CF
₹-38.5
Net profit
1,047
Price to book value
5.46
Interest Coverage
₹9.56
Low price all time
109.0
Industry PE
32.7
Reserves
₹8,821
Free Cash Flow
₹-1,575

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
GLENMARK PHARMACEUTICALS LTD.NANANANA48,29036.6
BIOCON LTD.44539.04594.044170.02.874738249.3
Narayana Hrudayalaya LimitedNANANANA4625158.1

Peer Comparison Chart


About GLENMARK PHARMACEUTICALS

Glenmark Pharmaceuticals ltd, with Security Code 532296, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Glenmark Pharmaceuticals Sees Surge in Open Interest Amid Increased Trading Activity

(28 Jun 2025)
Glenmark Pharmaceuticals Ltd. has seen a notable rise in open interest, reaching 57,132 contracts, alongside a trading volume of 53,947...
Read more →

Glenmark Launches a Transformative Nutrition and Livelihood Project in Emali, Kenya

(27 Jun 2025)
PRNewswire/ -- Glenmark Pharmaceuticals Kenya Limited, a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, a research-led global...
Read more →

10 Stocks To Buy For Short Term: Analysts suggest buying largecap, midcap scrips for 2 weeks; Glenmark Pharma, LIC, HPCL on the list

(27 Jun 2025)
Stocks To Buy: Brokerage Axis Direct picked ten stocks that can generate profits in 0 to 15 days. These are Glenmark Pharma, LIC, HPCL,...
Read more →

Glenmark Pharmaceuticals shares up 3% on launching cancer drug Tevimbra

(26 Jun 2025)
Glenmark Pharmaceuticals share price gained in trade after the company announced the launch of Tevimbra (tislelizumab) in India,...
Read more →

Glenmark Pharma launches lung cancer treatment drug in India; shares up 2%

(25 Jun 2025)
The lung cancer treatment drug Tevimbra has also been approved and marketed in multiple leading global markets, including the United States,...
Read more →

Glenmark Pharma rolls out TEVIMBRA for cancer care in India

(25 Jun 2025)
Glenmark Pharmaceutical, a research-led, global pharmaceutical company, launched TEVIMBRA® (tislelizumab) in India following the approval by...
Read more →